HIV Infections Clinical Trial
Official title:
HIV Prevention Among Alternative School Youth
The purpose of the study is to adapt, implement, and evaluate an effective
theoretically-based, high school HIV prevention program,Safer Choices, for higher risk youth
in alternative schools.
Primary Research Question
1. Did the intervention reduce the number of occasions of unprotected sexual intercourse,
number of sexual partners, and the proportion of students currently sexually active among
those receiving the multiple component intervention relative to those students in the
comparison group?
This is a group-randomized intervention trial to reduce sexual risk-taking behaviors among
young people attending alternative schools with a slight modification in the typical,
group-randomized study design.
We will conduct the study in two waves. For Wave One, we will randomize 10 alternative
schools (5 to intervention and 5 to comparison conditions), and then recruit and enroll a
cohort of 500, 9th-grade students into the study (cohort 1). For Wave Two, we will
cross-over the treatment conditions among the schools and enroll a new cohort of 9th-grade
students into the study. Prior to the intervention, we will conduct a baseline measurement
and conduct a post-intervention measurement at 6-, 12- and 24-months. The major hypothesis
to be tested is that adolescents attending alternative schools who receive a multi-component
HIV/STD intervention will reduce levels of unprotected sexual intercourse relative to those
in the comparison condition. The major dependent variables are unprotected sexual
intercourse, number of sexual partners, and proportion currently sexually active (last 3
months).
The specific aims of this project are to:
1. Adapt a tested, school-based, multi-component HIV prevention intervention for high-risk
adolescents attending alternative schools using qualitative data from the target
population and community representatives.
2. Assess the community acceptance, cultural sensitivity, and relevance of the proposed
program for the target population.
3. Evaluate the effect of the multi-component HIV intervention on sexual risk-taking
behaviors (unprotected sexual intercourse, number of sexual partners, deciding not to
have sexual intercourse) among high-risk youth attending alternative schools.
4. Evaluate the effect of the multi-component HIV intervention on decreasing other
risk-taking behaviors such as substance use and needle sharing behavior among youth
attending alternative schools.
5. Evaluate the effect of the multi-component HIV intervention on student impact variables
such as knowledge, self efficacy, attitudes, barriers, and perceived norms among youth
attending alternative schools.
6. Disseminate findings to the scientific community, school districts, and community
agencies.
We will conduct this study among 9th- grade students attending alternative schools in
Houston Independent School District (HISD) and other community alternative schools. HISD
Central Administration and Community Education Partners, the major HISD contractor, for
alternative schools have agreed to participate in the study. We have identified ten
alternative schools that have agreed to participate in the study. Students who are enrolled
in alternative schools are fairly heterogeneous in terms of the rationale for being in these
types of programs. Students may be in these programs for a variety of reasons including, low
school performance, high absenteeism, truancy, behavior problems, social problems,
pregnancy, or being in the juvenile justice system. However, all of the students enrolled in
the identified schools are considered high-risk adolescents. We have identified 10 schools
that have agreed to participate in the study with a total number of students enrolled in 9th
grade at over 1000 students per year providing a more than adequate target population for
recruitment. Of these students, 36% are African-American and 60% are Hispanic. Approximately
43% of the population are female.
Parental and student consent will be secured prior to administration of the risk assessment.
Procedures will be used to achieve high rates of parental consent including sending
information home about the project with particular emphasis on the confidential nature of
the risk assessment.
Risk assessment data will be collected by using a talking, interactive computer for the
collection of baseline, 6-month, 12-month, and 24-month post-intervention followup.
Baseline data collection will be conducted in the schools. The data collection staff will
give a brief overview of how to use the computer and will help them to enter basic
demographic information to acquaint them with the procedures. The computer will be equipped
with headphones to maintain privacy, and the respondent can ask questions to our data
collection staff, if needed. Post-intervention risk assessments will be conducted in the
schools as youth are still enrolled in the alternative school program. We expect that the
majority of students will still be enrolled in the alternative school at the 6-month
followup, but that the 12-month and 24-month follow up will have to be conducted in various
locations. We will track students enrolled in the study and conduct their follow up
assessments in school, home, or in a location that is mutually agreed upon.
Curriculum Component We will adapt an existing curriculum, Safer Choices, to high-risk
alternative school youth by obtaining feedback from the target population, conducting focus
groups with parents and youths, and by obtaining feedback from community agencies through
the Community Advisory Board. Although, Safer Choices was found to be effective in reducing
unprotected sexual intercourse among inner-city high school students in Houston, the
curriculum may need to be adapted to the experiences of these alternative school youth.
The target population has much higher prevalence of risk behaviors at younger ages than
adolescents in regular schools.Further, these youth are at much greater risk of abusing
drugs, being involved with legal authorities, being from single family households, having
lower social support, having academic difficulties and learning disabilities, having suicide
ideation and depression, and living in poorer communities. In adapting the program,
therefore, we face the challenge of making the program fit the setting and students in
alternative schools.
The curriculum will be designed to change students' knowledge, perceptions of norms,
beliefs, self-efficacy, interpersonal skills (i.e., refusal skills), and high-risk behaviors
related to HIV. The curriculum will include use of peer facilitators for selected lessons
such as role playing. Intervention strategies will include demonstrations of skills by role
playing, use of role model stories, and other experiential learning techniques. The Safer
Choices curriculum will be modified to combine the 9th and 10th grade lessons to select
those lessons which best match with the learning objectives for high-risk youth. The
curriculum will be delivered during the school days by facilitators (project staff) who will
receive intensive training prior to implementation and coaching and support during
implementation. The Teacher Training Protocol used for Safer Choices will be adapted to
train facilitators.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |